NO20023010L - Forbedring av nukleinsyre-vaksinering - Google Patents

Forbedring av nukleinsyre-vaksinering

Info

Publication number
NO20023010L
NO20023010L NO20023010A NO20023010A NO20023010L NO 20023010 L NO20023010 L NO 20023010L NO 20023010 A NO20023010 A NO 20023010A NO 20023010 A NO20023010 A NO 20023010A NO 20023010 L NO20023010 L NO 20023010L
Authority
NO
Norway
Prior art keywords
nucleic acid
enhancement
glycosylation
acid vaccination
isolated polynucleotide
Prior art date
Application number
NO20023010A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023010D0 (no
Inventor
James Scott Crowe
Jonathan Henry Ellis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20023010D0 publication Critical patent/NO20023010D0/no
Publication of NO20023010L publication Critical patent/NO20023010L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20023010A 1999-12-22 2002-06-21 Forbedring av nukleinsyre-vaksinering NO20023010L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930359.6A GB9930359D0 (en) 1999-12-22 1999-12-22 Novel polypeptides
PCT/GB2000/004906 WO2001046228A2 (en) 1999-12-22 2000-12-20 Nucleic acid vaccination

Publications (2)

Publication Number Publication Date
NO20023010D0 NO20023010D0 (no) 2002-06-21
NO20023010L true NO20023010L (no) 2002-08-06

Family

ID=10866857

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023010A NO20023010L (no) 1999-12-22 2002-06-21 Forbedring av nukleinsyre-vaksinering

Country Status (21)

Country Link
US (2) US20030133909A1 (pt)
EP (1) EP1240317B1 (pt)
JP (1) JP2003517845A (pt)
KR (1) KR20020073149A (pt)
CN (1) CN1434862A (pt)
AT (1) ATE355365T1 (pt)
AU (1) AU2204901A (pt)
BR (1) BR0016672A (pt)
CA (1) CA2395208A1 (pt)
CZ (1) CZ20022192A3 (pt)
DE (1) DE60033690T2 (pt)
ES (1) ES2282156T3 (pt)
GB (1) GB9930359D0 (pt)
HU (1) HUP0203848A3 (pt)
IL (1) IL150285A0 (pt)
MX (1) MXPA02006313A (pt)
NO (1) NO20023010L (pt)
NZ (1) NZ519732A (pt)
PL (1) PL356697A1 (pt)
WO (1) WO2001046228A2 (pt)
ZA (1) ZA200204987B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
MX2018008797A (es) 2016-01-19 2018-11-29 Pfizer Vacunas contra el cancer.
CN106086050B (zh) * 2016-06-28 2020-01-07 中国人民解放军第二军医大学 携带muc1肿瘤抗原表位pdtrp的嵌合型病毒样颗粒及在胰腺癌中的应用
JP7385556B2 (ja) 2017-09-01 2023-11-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695766A (en) * 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
DE19516673A1 (de) * 1995-04-28 1996-10-31 Gabriele Dr Pecher Vakzine gegen Tumorerkrankungen
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
JP2001510440A (ja) * 1996-03-20 2001-07-31 スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ ムチン接合体ペプチドワクチン
US5744177A (en) * 1996-06-11 1998-04-28 Lin; Rong-Teng Injection molding assembly

Also Published As

Publication number Publication date
MXPA02006313A (es) 2002-11-29
US20030133909A1 (en) 2003-07-17
IL150285A0 (en) 2002-12-01
CA2395208A1 (en) 2001-06-28
HUP0203848A2 (hu) 2003-03-28
JP2003517845A (ja) 2003-06-03
ATE355365T1 (de) 2006-03-15
HUP0203848A3 (en) 2004-07-28
PL356697A1 (en) 2004-06-28
WO2001046228A3 (en) 2002-01-17
EP1240317B1 (en) 2007-02-28
NO20023010D0 (no) 2002-06-21
CZ20022192A3 (cs) 2002-11-13
ES2282156T3 (es) 2007-10-16
DE60033690D1 (de) 2007-04-12
CN1434862A (zh) 2003-08-06
GB9930359D0 (en) 2000-02-09
NZ519732A (en) 2004-03-26
KR20020073149A (ko) 2002-09-19
AU2204901A (en) 2001-07-03
US20070269451A1 (en) 2007-11-22
EP1240317A2 (en) 2002-09-18
ZA200204987B (en) 2003-09-22
BR0016672A (pt) 2002-10-08
DE60033690T2 (de) 2007-11-08
WO2001046228A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
AU539535B2 (en) Recombinant dna molecules
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
FI971783A7 (fi) Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä
NO20023010L (no) Forbedring av nukleinsyre-vaksinering
EP0828003A3 (en) Human serine protease
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
WO2002048329A3 (en) Membrane derived caspase-3, compositions comprising the same and methods of use therefor
ITFI20000020A0 (it) Gel di acido ialuronico cross-linked con l-amminoacidi o l-amminoesteri bifunzionali
HUP9801384A2 (hu) Klostridium perfringens vakcina
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
DK312787D0 (da) Polypeptider, fremgangsmaade til deres fremstilling, dna som koder for polypeptiderne, vektorer indeholdende saadanne gensekvenser og laegemidler indeholdende polypeptiderne
DE69333304D1 (de) Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen
DE59410221D1 (de) Rekombinante chladosporium herbarum allergene
IL146191A0 (en) Viral expression vectors
WO1998024912A3 (en) Recombinant plague vaccine
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
ATE406446T1 (de) Vermehrungsproteine von pflanzen
WO2004003009A3 (en) Francisella tularensis immunogenic proteins and dna encoding these
PT672157E (pt) Virus recombinantes de local de clivagem proteolitica artificial
WO2000058486A3 (en) Maize ku80 homolog and uses thereof
EP1275716A3 (en) Modified DNA molecule, recombinant containing the same thing, and uses thereof
NO20021255L (no) Nye cellecykelsjekkpunktsgener og proteiner kodet derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application